University of Cincinnati researchers say they have discovered a new therapy for transplant patients; targeting the antibody-producing plasma cells that can cause organ rejection. Steve Woodle, MD, and colleagues found that a cancer drug. bortezomib, that is used to treat multiple myeloma
, or cancer of the plasma cells, is also effective in treating rejection episodes caused by antibodies that target transplanted kidneys and reversing rejection episodes that did not respond to standard therapies.
B-lymphocytes, or B cells, play a large role in the humoral immune response by making immune proteins that attack transplanted organs.